Computationally designed stapled peptides successfully entered human immune cells and suppressed NLRP3 inflammasome activation, blocking the release of inflammatory cytokines IL-1β and IL-18 — the first demonstration of stapled peptides targeting this key inflammation pathway.
First Stapled Peptides Targeting ASCThese computationally designed peptides are the first to successfully disrupt NLRP3 inflammasome assembly by targeting the ASC adaptor protein, blocking IL-1β and IL-18 release
What the researchers found
The stapled peptides achieved multiple validated effects in human monocytic cells (THP-1): they were effectively internalized, reduced ASC speck formation (the visible sign of inflammasome assembly), suppressed caspase-1 processing, and inhibited both pro-IL-1β processing and the release of active IL-1β and IL-18 following NLRP3 inflammasome activation.
The peptides were designed using molecular modeling guided by molecular dynamics simulations to adopt α-helical conformations that specifically target the pyrin domain of ASC. By disrupting ASC filament formation — a crucial structural step in inflammasome assembly — the peptides blocked the entire downstream inflammatory cascade. This represents the first successful proof-of-concept for stapled peptides targeting ASC in the NLRP3 pathway.
Why it matters
The NLRP3 inflammasome is implicated in a huge number of diseases affecting billions of people — atherosclerosis, diabetes, obesity, gout, Alzheimer's, and more. Current anti-IL-1β therapies (like the antibody canakinumab) are expensive and broadly immunosuppressive. Stapled peptides that specifically disrupt inflammasome assembly could offer more targeted anti-inflammatory therapy with potentially fewer side effects. This proof-of-concept opens a new therapeutic modality for inflammasome-driven diseases.
How the study worked
The researchers used computational molecular modeling and molecular dynamics simulations to design α-helical stapled peptides targeting the pyrin domain of the ASC adaptor protein. Peptide cellular uptake was assessed in human monocytic THP-1 cells. Functional validation included measuring IL-1β and IL-18 release, ASC speck formation, and caspase-1 processing following NLRP3 inflammasome activation with standard triggers (LPS priming + nigericin).
What this study cannot tell us
All experiments were performed in vitro using a single cell line (THP-1 human monocytic cells). No in vivo animal testing was reported. The pharmacokinetics, stability, and potential off-target effects of these stapled peptides in living organisms are unknown. The specificity of the peptides for NLRP3 over other inflammasome types was not fully characterized. Manufacturing scalability and cost were not addressed.
How to read the evidence
This is an in vitro proof-of-concept study in a human monocytic cell line. While the computational design approach is sophisticated and the functional results compelling, the absence of in vivo data means this is early-stage preclinical evidence that requires extensive further validation.
When this study was published
Published in 2019, this study predates several major advances in both stapled peptide drug development and inflammasome biology. The proof-of-concept it established has since informed ongoing efforts to develop peptide-based inflammasome inhibitors.
The bigger picture
Stapled peptides are an emerging drug class that bridges the gap between small molecule drugs and biologics. By chemically reinforcing peptides to maintain their active shape, they gain improved cellular uptake and stability. This study expands the stapled peptide platform to inflammatory disease targets, joining ongoing efforts in cancer (stapled peptides targeting p53-MDM2) and other fields. The ability to computationally design peptides that disrupt specific protein-protein interactions within the inflammasome represents a precision approach to anti-inflammatory drug development.
Questions still open
- How do these stapled peptides perform in animal models of inflammasome-driven diseases like atherosclerosis or diabetes?
- Can this approach be extended to selectively target other inflammasome types (AIM2, NLRC4) while sparing NLRP3?
- What is the therapeutic window — how much inflammasome suppression is beneficial without compromising necessary immune defense?
Common questions
What are stapled peptides and why are they special?
What is the NLRP3 inflammasome and why is it important?
Read the original research
Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides.
Scientific reports, 9(1), 4913
Citation
Pal, Arumay; Neo, Kurt; Rajamani, Lakshminarayanan; Ferrer, Fernando Jose; Lane, David P; Verma, Chandra S; Mortellaro, Alessandra. (2019). Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides.. Scientific reports, 9(1), 4913. https://doi.org/10.1038/s41598-019-41211-3